Alembic Pharmaceuticals is currently trading at Rs. 522.65, up by 8.90 points or 1.73% from its previous closing of Rs. 513.75 on the BSE.
The scrip opened at Rs. 525.90 and has touched a high and low of Rs. 526.75 and Rs. 517.15 respectively. So far 1132 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 588.00 on 15-Feb-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 533.00 and Rs. 508.55 respectively. The current market cap of the company is Rs. 9685.01 crore.
The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 14.30% and 12.74% respectively.
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection carried out by them at our API Facility at Karakhadi in the state of Gujarat during the period from May 14, 2018 to May 18, 2018.
With this, all the company’s manufacturing facilities for international markets are FDA compliant.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
